PPIA and non-small cell lung carcinoma: In addition, to further clarify the effects of the CypA inhibitors and the mode of EGFR downregulation in EGFR-mutant NSCLC CSCs, it is necessary to evaluate the anticancer activities of C9 and CsA using CSCs derived from different types of EGFR-mutant NSCLC cell lines.